Press Releases

Endonovo Therapeutics Granted Trademarks for WoundPulse and OrthoHalo

Download PDF

LOS ANGELES, CA, March 22, 2019 (GLOBE NEWSWIRE) -- March 22, 2019 -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a commercial-stage developer of non-invasive Electroceutical™ therapies brand, today announced the U.S. Patent and Trademark Office has awarded the company a trademark on their patented technology for WoundPulse™ and OrthoHalo™.

The trademark includes DEVICES AND METHOD FOR TREATMENT OF DEGENERATIVE JOINT DISEASES WITH ELECTROMAGNETIC FIELDS which will be included under its WOUNDPULSE™ brand. U.S. Serial Number: 88184047

The trademark includes ELECTROMAGNETIC THERAPY APPARTUS FOR CLINICAL MEDICAL USE IN THE TREATMENT OF TISSUE GROWTH AND REPAIR which will be included under its ORTHOHALO™ brand. U.S. Serial Number: 88173679

Alan Collier, CEO of Endonovo Therapeutics, stated, “We’re very excited about this development which reflects years of hard work by our world-class technology development organization and partners, combined with product input from medical professionals. The intellectual property protected by these trademarks play a crucial role in Endonovo’s ability to deliver significantly richer platform to scale and empower healthcare professionals to provide patients a better and safer way to manage pain without the adverse side effects of narcotics and anti-inflammatory medication.”

About Endonovo Therapeutics

Endonovo Therapeutics, Inc. is a commercial-stage developer of non-invasive wearable Electroceuticals™ Therapies brand. The Company's current portfolio of commercial and clinical-stage wearable Electroceuticals™ Therapies brand addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and Central Nervous System (CNS) Disorders, including traumatic brain injury (TBI), acute concussions, post-concussion syndrome and multiple sclerosis. The Company's non-invasive Electroceutical™ System device, SofPulse® brand, using pulsed short-wave radiofrequency at 27.12 MHz has been FDA-Cleared and CE Marked for the palliative treatment of soft tissue injuries and post-operative pain and edema, and has CMS National Coverage for the treatment of chronic wounds. The Company's current portfolio of pre-clinical stage Electroceuticals™ brand addresses chronic kidney disease, liver disease non-alcoholic steatohepatitis (NASH), cardiovascular and peripheral artery disease (PAD), and ischemic stroke. The Company's non-invasive, wearable Electroceuticals™ brand work by restoring key electrochemical processes that initiate anti-inflammatory and growth factor cascades necessary for healing to occur.

Safe Harbor Statement

This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, trends, analysis, and other information contained in this press release including words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," and other similar expressions of opinion, constitute forward-looking statements. Any such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any future results described within the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company's reports filed with the Securities and Exchange Commission. The forward-looking information provided herein represents the Company's estimates as of the date of the press release, and subsequent events and developments may cause the Company's estimates to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company's estimates of its future financial performance as of any date subsequent to the date of this press release.

Investor Relations Contact: 

Endonovo Therapeutics, Inc. 
Mr. Andrew Barwicki

Source: Endonovo Therapeutics, Inc.